Navigation Links
Ariosa Diagnostics Selected as NIPT Service Provider in Majority of California Comprehensive Prenatal Diagnosis Centers Throughout the State
Date:11/1/2013

SAN JOSE, Calif., Nov. 1, 2013 /PRNewswire/ -- Ariosa Diagnostics, Inc., maker of the Harmony™ Prenatal Test, announced today that it has been selected as a key provider of non-invasive prenatal testing (NIPT) services in the majority of the 28 comprehensive Prenatal Diagnosis Centers (PDC) throughout the State of California. The Harmony test, which is the most widely used NIPT globally, is being offered to pregnant women as part of the California Prenatal Screening Program at no additional cost, subject to the program requirements.

(Logo: http://photos.prnewswire.com/prnh/20130225/SF62999LOGO)

Currently, the California Prenatal Screening Program offers traditional serum and neural tube defect screening to the general population of pregnant women. Patients found to be screen positive for possible chromosome conditions (such as Down syndrome or trisomy 18), or have an increased nuchal translucency measurement, are referred for other services that include genetic counseling, ultrasound, amniocentesis and chorionic villus sampling (CVS). Given its increased sensitivity and specificity, the State has now introduced NIPT as another option in evaluating patients who have an increased risk for chromosome conditions based on their serum screening results. 

The Harmony test has the most published data of any NIPT available for pregnant women of any age, fetal gestational age and risk-profile. Published in over 13 peer-reviewed studies, involving thousands of patients, the test has demonstrated greater than 99% accuracy for Down syndrome with a less than 0.1% false positive rate, thereby diminishing the potential for women to unnecessarily proceed to invasive diagnostic procedures that may result in pregnancy complications in an otherwise normal fetus.  

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the HarmonyTM Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The HarmonyTM Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com. Follow us on Twitter @HarmonyPrenatal and on Facebook at Harmony Prenatal for Healthy Pregnancy.

CONTACT:
Jen Bruursema
408-229-7539
jbruursema@ariosadx.com


'/>"/>
SOURCE Ariosa Diagnostics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ariosa Diagnostics Wins Summary Judgment Against Sequenom on Cell-free DNA Patent
2. Ariosa Diagnostics Introduces Y-Chromosome Analysis Test Option
3. Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy
4. PDI, Inc. Appoints Molecular Diagnostics Leader to Board of Directors
5. Does Your Business Have the Tools to Compete in the Worlds Largest Diagnostics Markets?
6. Exagen Diagnostics Appoints New Board Member
7. Frost & Sullivan Unveils Future Opportunities for the Tissue Diagnostics Market
8. DNA Diagnostics Center (DDC), One of the Worlds Largest DNA Testing Companies, Increases the Identification Power of its DNA Tests by More Than 500%
9. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
10. Life Technologies and Advanced Cell Diagnostics Sign Global Distribution Agreement
11. Increasing Public Health Awareness Intensifies Global Uptake of Autoimmune Disease Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):